PHG

Koninklijke Philips
D

PHG

Arincen44/100B

If you had invested in Koninklijke Philips ago, it would be worth $1,498 today, against $4,096 in SPY and $6,368 in QQQ.

ArincenArincen ScoreBeta

44/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation—

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Koninklijke Philips key facts

Style
Value stock · 7.0/10Growth 1.8 · Value 7.0 · Dividend 6.9
Day range
30.300 – 30.500
52-week range
23.620 – 33.440
Market capitalization
29.56B USD
P/E
27.59
PEG ratio
0.79
EPS
1.10
Div Yield
3.26%
EPS growth forecast (FY2026)
+4.8%
Volume
18,397
Beta
0.92
ESG score
69.4/100Environment 67 · Social 73 · Governance 68
Sector
Healthcare
Industry
Medical - Devices
CEO
Roy W. O. Jakobs
Employees
66K
Website
philips.ca
IPO date
17 Mar 1980

Koninklijke Philips earnings

Next earnings · Q4 FY2026
EPS estimate
0.61 USD
Revenue estimate
6.00B USD
Last quarter · Q3 FY2026
EPS0.46Beat +24.3%Revenue4.93BMissed -1.6%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q4 FY20260.61——-12.86%6.00B——-1.14%
Q3 FY20260.370.46+24.32%+24.32%5.01B4.93B-1.63%-2.25%
Q2 FY20260.400.57+42.50%+39.02%4.91B4.96B+1.19%-2.81%
Q1 FY20260.240.27+12.50%0.00%4.49B4.59B+2.19%-1.25%
Q4 FY20250.570.70+23.89%+29.63%5.89B6.07B+3.12%+16.27%
Q3 FY20250.370.370.00%+5.71%5.03B5.04B+0.12%+4.96%
Q2 FY20250.320.41+29.17%+28.13%4.30B5.11B+18.67%+6.46%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

Koninklijke Philips analyst forecast

Strong sellStrong buy
Hold
1 ratings
Buy
0
Hold
1
Sell
0

Koninklijke Philips valuation

Price to earnings ratio (TTM)
27.59
Forward P/E (FY2026)
16.58
Price to sales (TTM)
1.51
Price to book
2.27
EV / EBITDA (TTM)
10.28

Capital structure

Market capitalization
29.56B USD
+
Total debt
9.15B USD
−
Cash and short-term investments
3.09B USD
=
Enterprise value
35.61B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2027 (est.)16.29————
FY2026 (est.)16.5816.29———
Now (TTM)27.5916.331.512.2710.28
FY202524.2613.901.242.0210.41
FY2024-32.6011.911.271.9015.10
FY2023-41.6511.911.071.6123.81
FY2022-8.339.980.751.01169.60
FY202144.7738.861.591.8915.51

Koninklijke Philips against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings, Edwards Lifesciences, Boston Scientific, and Glaukos, the US Medical - Devices companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • Gross marginHighest in 5 years45.2%
    40.4%45.2%
    Against its peers: 6 of 7Peers' median 65.3%
  • Operating marginHighest in 5 years8.0%
    -8.6%8.0%
    Against its peers: 6 of 7Peers' median 18.1%
  • Net marginAbove its median5.0%
    -9.0%19.3%
    Against its peers: 6 of 7Peers' median 12.2%
  • Return on equityAbove its median8.2%
    -12.1%23.0%
    Against its peers: 5 of 7Peers' median 11.1%
  • Free cash flow marginBelow its median5.0%
    -3.6%10.7%
    Against its peers: 6 of 7Peers' median 18.1%
  • Revenue growthLowest in 5 years-1.0%
    -1.0%3.9%
    Against its peers: 7 of 7Peers' median 13.6%
  • Debt to EBITDABelow its median3.06×
    3.03×63.84×
    Against its peers: 5 of 6Peers' median 2.43×
  • Current ratioAbove its median1.32
    1.201.39
    Against its peers: 6 of 7Peers' median 1.93

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Koninklijke Philips growth and profitability

Revenue (TTM)
17.73B EUR
Net income (TTM)
956.84M EUR
Gross margin
46.43%
Operating margin
10.50%
Net margin
5.40%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202517.83B-1.04%895.00M—45.18%7.98%5.02%2.64B+42.74%
FY202418.02B-0.81%-702.00M—43.13%2.94%-3.90%1.85B+77.62%
FY202318.17B+1.92%-466.00M—40.99%-0.63%-2.56%1.04B+805.22%
FY202217.83B+3.91%-1.61B-148.45%40.35%-8.58%-9.02%115.00M-94.24%
FY202117.16B-0.91%3.32B+179.61%41.78%3.22%19.35%2.00B-36.57%

Koninklijke Philips revenue breakdown

By region

FY2025
United States: 40.0%Other countries: 30.4%Netherlands: 14.3%China: 6.7%Japan: 5.0%Germany: 3.7%40.0%United States30.4%Other countries14.3%Netherlands6.7%China5.0%Japan3.7%Germany
RegionRevenueShare of revenueChange on the year
United States7.13B40.0%-1.3%
Other countries5.42B30.4%-3.1%
Netherlands2.55B14.3%+1.6%
China1.20B6.7%+4.2%
Japan883.00M5.0%-0.3%
Germany652.00M3.7%-0.2%

How Koninklijke Philips makes its money

Revenue17.83B 100.0%
Cost of revenue9.78B 54.8%
Gross profit8.06B 45.2%
Research and development1.70B 9.5%
Selling and administration4.97B 27.9%
Operating income1.42B 8.0%
Tax282.00M 1.6%
Other expense247.00M 1.4%
Net income895.00M 5.0%

FY2025, in EUR. Each band is as wide as its money; the percentage is its share of revenue.

Koninklijke Philips dividends

Annual dividend
0.99 USD
Dividend yield (indicated)
3.26%
Payout ratio
89.82%
Years of dividend growth
2
Frequency
Annual
Last payment
0.99 USD
Last ex-dividend date
13 May 2026
Last payment date
3 Jun 2026

Dividends per share

Year2025202420222021202020192018201720162015
Dividends per share0.970.920.961.030.800.960.990.860.880.91

Koninklijke Philips financial health

Cash and short-term investments
2.80B EUR
Total debt
8.28B EUR
Net cash
-5.48B EUR
Free cash flow (TTM)
2.11B EUR
Current ratio
1.33
Debt to equity
0.70
Piotroski score
7 / 9
Altman Z-score
2.08

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20252.79B8.09B893.00M
FY20242.40B7.49B1.35B
FY20231.87B7.29B1.94B
FY20221.18B7.34B-648.45M
FY20212.31B6.05B1.46B

Koninklijke Philips ownership

Institutions
5.40%
Institutional holders
377 (+24)
Free float
99.96%

Who owns the shares

Institutions 5.4% Others 94.6%
As of 30 Jun 2026

Shares free to trade

Free float 971.59M shares ·100.0% Closely held 436.93K shares ·0.0%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025962.37M962.50M+3.12%
FY2024933.37M933.37M-1.62%
FY2023948.79M948.79M-0.39%
FY2022952.46M952.46M+0.23%
FY2021907.46M950.28M-0.76%

Source: Financial Modeling Prep

Related Instruments

Title: Koninklijke Philips NV

Sector: Healthcare
Industry: Medical - Devices
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.

Common questions about Koninklijke Philips stock